Uncategorized

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

LadRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc., together with NantCell’s parent company ImmunityBio, Inc., have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017.

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License Read More »

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax in combination with azacitidine in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia, in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety Read More »

Scroll to Top